MBX Company Profile and Key Details

NASDAQ : MBX

MBX Biosciences Common Stock

$62.91

-0.08-0.13%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

MBX Biosciences, Inc. Common Stock (MBX) stock declined over -0.13%, trading at $62.91 on NASDAQ, down from the previous close of $62.99. The stock opened at $63.29, fluctuating between $61.29 and $64.04 in the recent session.

Stock Snapshot

62.99

Prev. Close

2.99B

Market Cap

61.285

Day Low

-26.1

P/E Ratio

-2.41

EPS (TTM)

N/A

Cash Flow per Share

63.29

Open

47.6M

Number of Shares

64.04

Day High

43.49%

Free Float in %

N/A

Book Value

315.68K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 09, 2026	63.29	64.04	61.29	62.91	315.68K
Sep 08, 2026	60.85	64.17	60.66	62.99	265.96K
Sep 04, 2026	61.00	62.73	60.60	61.72	271.77K
Sep 03, 2026	60.90	62.61	59.84	61.42	292.5K
Sep 02, 2026	61.40	62.45	58.80	60.89	352.28K
Sep 01, 2026	61.42	62.88	60.22	60.93	416.08K
Aug 31, 2026	62.25	63.04	59.47	61.60	518.3K
Aug 28, 2026	66.14	66.14	62.99	63.00	307.65K
Aug 27, 2026	66.73	66.90	64.50	66.39	263.54K
Aug 26, 2026	68.56	68.83	66.27	66.76	214.66K
Aug 25, 2026	67.64	69.50	67.64	68.62	273.99K
Aug 24, 2026	66.23	67.16	64.00	66.39	531.03K
Aug 21, 2026	67.86	67.86	65.59	66.33	466.34K
Aug 20, 2026	67.00	68.49	65.40	66.35	422.49K
Aug 19, 2026	67.53	68.76	65.25	68.40	562.28K
Aug 18, 2026	66.40	69.05	65.80	66.52	560.71K
Aug 17, 2026	68.28	69.94	67.58	68.25	460.08K
Aug 14, 2026	67.00	68.84	65.01	68.57	503.13K
Aug 13, 2026	66.97	68.41	65.50	67.08	334.91K
Aug 12, 2026	66.84	67.80	66.00	66.97	331.43K

Contact Details

Carmel, IN 46032

United States

https://mbxbio.com 317 659 0200

About Company

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Stock Peers

ARGX

-4.76-0.47%

argenx SE$1,002.31 REGN

-2.66-0.33%

Regeneron Pharmaceuticals, Inc.$807.65 MDGL

12.5+2.34%

Madrigal Pharmaceuticals, Inc.$546.66 VRTX

-7.78-1.47%

Vertex Pharmaceuticals Incorporated$521.12 UTHR

8.85+1.78%

United Therapeutics Corporation$506.82 ONC

-0.48-0.14%

BeOne Medicines AG$351.00 KRYS

-3.17-0.90%

Krystal Biotech, Inc.$348.09 PRAX

-7.18-2.04%

Praxis Precision Medicines, Inc.$345.30 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-0.78-0.27%

Ligand Pharmaceuticals Incorporated$288.05

Company Overview

MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) closed at $62.91 USD, losing -$0.08 (-0.13%) from the previous close of $62.99. The stock is currently mid-range between its 52-week high and low $9.63 and $72.64. With a market capitalization of about $2.99 billion, MBX Biosciences, Inc. Common Stock is classified as a mid-cap and shows lower-than-market volatility (beta ~0.10). Key stats such as the average daily volume over the past year has been around 740.73 thousand shares, volume is running light vs its 52-week average. Headquartered in Carmel, IN, MBX Biosciences, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steve Hoerter, the company employs approximately 63 people and listed since September 13, 2024. MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions.

Technical Performance

MBX has shown sold momentum, gaining 18.29% over the past week and 226.32% over the past quarter, though year-to-date performance is up 36.78%. Short-term trend indicators are bearishly aligned (SMA20 -6.03%, SMA50 -0.79%, SMA200 66.92%). The stock’s 14-day RSI is 45.7 (neutral), while the ATR of 2.88 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -21.94% below its high and over 628.95% above its low. Average 10-day trading volume of 347.51 thousand shares is below the 3-month average of 718.41 thousand, indicating normal recent market interest.

Valuation Metrics

MBX Biosciences, Inc. Common Stock trades at a P/E ratio of -25.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.19 trading at moderately above to book value. The P/FCF stands at -34.49, also below market averages.

Dividend & Fair Value

MBX Biosciences, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.05. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 14.35% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $91.00 to $18.00. The high target offers 44.65% upside. The low target suggests -71.39% downside. The mean target is $68.93. This offers 9.57% upside. MBX Biosciences, Inc. Common Stock earnings surprise history is frequent misses against expectations. The quarter that ended August 06, 2026, missed forecasts by 23.32%. The prior quarter beat by -17.74%. Over the last six quarters, Apple has recorded several small beats. These include -12.35% in May 12, 2025.

Shareholding & Insider Activity

MBX Biosciences, Inc. Common Stock has 48.16 million shares outstanding. The public float is 30.99 million shares, elevated short interest at 15.14% of float. This equals 5.19 million shares. The short ratio is 6.66 days. Institutional investors hold 123.78% of the float. Insiders own 2.7%. Heron Patrick J holds 5.22 million shares, Hawryluk P. Kent has 727.67 thousand shares and Pescovitz Ora H. has 24.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 16.21 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, MBX Biosciences Common Stock has not generated any revenue.
On valuation metrics, MBX Biosciences Common Stock trades at a P/E of -25.73, P/S of 0.00 and P/B of 7.19. The current ratio is 18.08 and quick ratio is 18.08. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -7097.95 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -24.74.

Price Forecast & Outlook

Our AI price prediction model suggests that MBX Biosciences, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.62%, with price expected at $56.23 by September 22, 2026, within a range of $53.81 to $58.67 3-Month Outlook: Projected rise of 85.2%, reaching $116.51 by December 07, 2026, with a range of $114.97 to $118.05. 1-Year Outlook: Projected gain of 42.14%, with price at $89.42 by September 08, 2027, within a range of $85.00 to $93.75.

Key Takeaways

MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) shares are up 36.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows MBX Biosciences, Inc. Common Stock trading at a premium to the broader market with a P/E of -25.73. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $57.38, suggesting -8.79% downside. Our AI forecast model points to short-term weakness (-10.62% over two weeks), a medium-term rise (85.2% over three months), and a longer-term gain (42.14% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current MBX Biosciences, Inc. Common Stock (MBX) stock price?

MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) stock price is $62.91 in the last trading session. During the trading session, MBX stock reached the peak price of $64.04 while $61.29 was the lowest point it dropped to. The percentage change in MBX stock occurred in the recent session was -0.13% while the dollar amount for the price change in MBX stock was - $0.08.

MBX's industry and sector of operation?

The NASDAQ listed MBX is part of Biotechnology industry that operates in the broader Healthcare sector. MBX Biosciences, Inc. Common Stock designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MBX?

No Data

How MBX did perform over past 52-week?

MBX's closing price is 553.27% higher than its 52-week low of $9.63 where as its distance from 52-week high of $72.64 is -13.39%.

How many employees does MBX have?

Number of MBX employees currently stands at 63.

Link for MBX official website?

Official Website of MBX is: https://mbxbio.com

How do I contact MBX?

MBX could be contacted at phone 317 659 0200 and can also be accessed through its website. MBX operates from 11711 N. Meridian Street, Carmel, IN 46032, United States.

How many shares of MBX are traded daily?

MBX stock volume for the day was 315.68K shares. The average number of MBX shares traded daily for last 3 months was 740.73K.

What is the market cap of MBX currently?

The market value of MBX currently stands at $2.99B with its latest stock price at $62.91 and 47.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	63
Beta	0.1
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

MBX Company Profile and Key Details

MBX Biosciences Common Stock

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Financial & Profitability Overview

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook

Valuation Metrics